MR-conditional quadripolar CRT pacemaker approved

Biotronik announced that it has launched the smallest MR conditional cardiac resynchronization therapy pacemaker in the U.S., recently approved by the FDA.

According to a press release from the company, the CRT-P (Edora HF-T QP) has a volume of 15 cc, a longevity of 10 years and could potentially reduce the number of device replacements required for HF patients.

The device includes the Biotronik Home Monitoring feature, which was associated with a greater than 50% reduction in mortality due to HF and a 36% reduction in hospitalization for worsening HF in recent studies, according to the release.

“Patient care is a constant journey. It doesn’t end when the patient leaves my office or recovers from a procedure,” Roderick Tung, a cardiac electrophysiologist and associate professor of medicine at University of Chicago Medicine, said in the release. “As healthcare providers, we must think beyond today and help ensure patients are appropriately cared for throughout their lifetime.”

According to the release, the device has AutoDetect technology, which minimizes the time the device is in MRI mode and addresses logistical programming challenges.

“MR conditional CRT-Ps that can be programmed to automatically switch to MRI mode when they enter the MRI environment are another significant step in delivering the best possible care throughout the patient journey,” Tung said in the release. “This technology eliminates an office visit for patients and decreases administrative burden for providers. The impact is significant, especially in institutions that perform cardiac MRI for advanced ventricular care.”

Disclosure: Cardiology Today could not confirm relevant financial disclosures.